Is it time to relax or tighten the legislation on human embryo research?
Over the past decade, human embryo research has generated both enormous scientific interest and extensive public debate. In response to this, Australia passed two Acts in 2002: the Research Involving Human Embryos Act 2002 (Cwlth) and the Prohibition of Human Cloning Act 2002 (Cwlth). Together, these Acts, and mirror legislation passed by all states and territories, enabled Australian scientists to undertake specific research involving human embryos, provided that they obtained a licence from the Embryo Research Licensing Committee of the National Health and Medical Research Council (NHMRC), reported regularly to this committee, and had their research approved and monitored by the appropriate institutional ethics committee. At the same time, these Acts prohibited a series of practices — including human cloning, creation of animal–human cybrids, maturation of research embryos beyond 14 days, and the buying and selling of human oocytes — and provided substantial penalties for breaches of the provisions.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Barbaric I, Gokhale PJ, Andrews PW. High-content screening of small compounds on human embryonic stem cells. Biochem Soc Trans 2010; 38: 1046-1050.
- 2. Khan A. First clinical trial begins for stem cell therapy. Los Angeles Times 2010; 12 Oct.
- 3. Sample I. Stem cells injected into the brain of a stroke patient in world first. Guardian 2010; 16 Nov. http://www.guardian.co.uk/science/2010/nov/16/stem-cells-injected-brain-stroke (accessed Nov 2010).
- 4. Vogel G. Second trial using human embryonic stem cells gets go-ahead. Science Insider 2010; 22 Nov. http://news.sciencemag.org/scienceinsider/2010/11/second-trial-using-human-embryonic.html (accessed Dec 2010).
- 5. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms and applications. Genes Dev 2010; 24: 2239-2263.
- 6. Kiskinis E, Eggan K. Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest 2010; 120: 51-59.
- 7. Yu J, Thomson JA. Pluripotent stem cell lines. Gene Dev 2008; 22: 1987-1997.
- 8. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
- 9. Csete M. Translational prospects for human induced pluripotent stem cells. Regen Med 2010; 5: 509-519.
- 10. Szabo E, Rampalli S, Risueno RM, et al. Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010; 468: 521-526.
- 11. Kaneko S, Otsu M, Nakauchi H. Reprogramming adult hematopoietic cells. Curr Opin Hematol 2010; 17: 271-275.
- 12. Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010; 465: 704-712.
Ian Kerridge is a Board Member of the NSW Stem Cell Network and was a member of the Lockhart Committee in 2006.